• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma.

作者信息

Sarkozy Clémentine, Seymour John Francis, Ferme Christophe, Caballero Dolores, Ghesquieres Hervé, Leppa Sirpa, Delarue Richard, Pedersen Lars Moller, Mounier Christiane, Gomes Da Silva Maria, Chassagne-Clement Catherine, Maerevoet Marie, Salles Gilles

机构信息

Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre-Bénite, France University Claude Bernard Lyon 1,Lyon, France.

出版信息

Blood. 2014 Apr 24;123(17):2740-2. doi: 10.1182/blood-2014-02-553693.

DOI:10.1182/blood-2014-02-553693
PMID:24764560
Abstract
摘要

相似文献

1
Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma.利妥昔单抗维持治疗可消除滤泡性淋巴瘤患者中与循环淋巴瘤细胞相关的不良预后。
Blood. 2014 Apr 24;123(17):2740-2. doi: 10.1182/blood-2014-02-553693.
2
Optimization of postremission therapy in follicular lymphoma: efficacy of rituximab maintenance.滤泡性淋巴瘤缓解后治疗的优化：利妥昔单抗维持治疗的疗效。
J Natl Compr Canc Netw. 2011 May;9(5):563-71. doi: 10.6004/jnccn.2011.0047.
3
Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy.在接受含利妥昔单抗治疗的滤泡性淋巴瘤中，组织学分级和 Bcl-2 表达强度的预后意义。
Hum Pathol. 2013 Nov;44(11):2529-35. doi: 10.1016/j.humpath.2013.06.013. Epub 2013 Jul 31.
4
Rituximab maintenance therapy for follicular lymphoma.利妥昔单抗用于滤泡性淋巴瘤的维持治疗。
Lancet. 2011 Apr 2;377(9772):1151; author reply 1151-2. doi: 10.1016/S0140-6736(11)60459-5.
5
Maintenance rituximab should be considered for patients with follicular lymphoma.对于滤泡性淋巴瘤患者，应考虑使用利妥昔单抗进行维持治疗。
Clin Adv Hematol Oncol. 2014 Aug;12(8):541-3.
6
Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.利妥昔单抗维持治疗可改善滤泡性淋巴瘤患者的总生存期——个体患者数据荟萃分析
Eur J Cancer. 2017 May;76:216-225. doi: 10.1016/j.ejca.2017.01.021. Epub 2017 Mar 21.
7
Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies.滤泡性非霍奇金淋巴瘤维持利妥昔单抗治疗：事实与争议。
Leuk Lymphoma. 2012 May;53(5):770-8. doi: 10.3109/10428194.2011.628061. Epub 2011 Oct 24.
8
Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.外周血淋巴细胞/单核细胞比值可预测利妥昔单抗时代滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤患者的预后。
Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):208-13. doi: 10.1016/j.clml.2014.10.001. Epub 2014 Oct 23.
9
Rituximab as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma: profile report.
BioDrugs. 2011 Oct 1;25(5):329-31. doi: 10.2165/11207200-000000000-00000.
10
Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.滤泡性淋巴瘤患者的外周血受累：一种与预后不良相关的罕见疾病表现。
Br J Haematol. 2014 Mar;164(5):659-67. doi: 10.1111/bjh.12675. Epub 2013 Nov 26.

引用本文的文献

1
Low-Grade Primary Splenic CD10-Positive Small B-Cell Lymphoma/Follicular Lymphoma.低级别原发性脾脏 CD10 阳性小 B 细胞淋巴瘤/滤泡性淋巴瘤。
Curr Oncol. 2021 Nov 18;28(6):4821-4831. doi: 10.3390/curroncol28060407.
2
Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy.血液中的绝对 B 细胞计数可预测未经化疗而接受利妥昔单抗治疗的滤泡性淋巴瘤患者的长期反应。
Ann Hematol. 2020 Oct;99(10):2357-2366. doi: 10.1007/s00277-020-04208-x. Epub 2020 Aug 17.
3
Updates on Circulating Tumor DNA Assessment in Lymphoma.
淋巴瘤循环肿瘤DNA评估的最新进展
Curr Hematol Malig Rep. 2018 Oct;13(5):348-355. doi: 10.1007/s11899-018-0468-4.
4
Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma.总代谢肿瘤体积、循环肿瘤细胞、游离细胞 DNA：滤泡性淋巴瘤的不同预后价值。
Blood Adv. 2018 Apr 10;2(7):807-816. doi: 10.1182/bloodadvances.2017015164.
5
EZH2 alterations in follicular lymphoma: biological and clinical correlations.滤泡性淋巴瘤中的EZH2改变：生物学与临床相关性
Blood Cancer J. 2017 Apr 21;7(4):e555. doi: 10.1038/bcj.2017.32.
6
The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma.滤泡性淋巴瘤患者诊断时克隆异质性及血浆循环克隆性IG-VDJ序列定量评估的预后价值
Oncotarget. 2017 Jan 31;8(5):8765-8774. doi: 10.18632/oncotarget.14448.
7
Haematological cancer: the translocation behind follicular lymphoma development.血液系统癌症：滤泡性淋巴瘤发展背后的易位
Nat Rev Clin Oncol. 2014 Aug;11(8):444-5. doi: 10.1038/nrclinonc.2014.100. Epub 2014 Jun 17.